Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
NNC0519-0130 by Novo Nordisk for Obesity: Likelihood of Approval
NNC0519-0130 is under clinical development by Novo Nordisk and currently in Phase II for Obesity. According to GlobalData, Phase II...
NNC0519-0130 by Novo Nordisk for Type 2 Diabetes: Likelihood of Approval
NNC0519-0130 is under clinical development by Novo Nordisk and currently in Phase II for Type 2 Diabetes. According to GlobalData,...
Risk adjusted net present value: What is the current valuation of Novo Nordisk's NNC0519-0130?
NNC0519-0130 is commercialized by Novo Nordisk, with a leading Phase II program in Type 2 Diabetes. According to Globaldata, it...